Immunochina Pharmaceuticals's last reported valuation, Sep 2020. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Immunochina Pharmaceuticals: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Immunochina Pharmaceuticals funding history
No funding rounds for Immunochina Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Immunochina Pharmaceuticals valuation
Immunochina Pharmaceuticals's last reported valuation was $215 million in Sep 2020. No priced round, secondary trade or fund mark has surfaced since.
How Immunochina Pharmaceuticals's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Immunochina Pharmaceuticals, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →
Frequently asked about Immunochina Pharmaceuticals
- What is Immunochina Pharmaceuticals worth?
- Immunochina Pharmaceuticals is valued at $215.3M as of Oct 2026. Immunochina Pharmaceuticals's last reported valuation, Sep 2020. Nothing priced has surfaced since.
- How much has Immunochina Pharmaceuticals raised?
- Immunochina Pharmaceuticals has raised $45.0M in total funding across its recorded rounds.